At AAN 2025, three posters presented the sustained long-term efficacy and real-world impact of Lundbeck’s Vyepti for migraine ...

W hen it comes to treating a chronic condition like migraine, Western medicine is the new kid on the block, relatively speaking. After all, the vast majority of today’s pharmace ...

Menstrual migraine affects more than half of people with both periods and migraine. Find out what you can do to manage this ...

Appropriate acute medications for symptom relief during migraine attacks, potentially including newer options like gepants or ditans ... anticonvulsants, CGRP pathway modulators, and others.

there is fierce competition with several oral CGRP drugs or 'gepants' on the market including AbbVie's Ubrelvy (ubrogepant) for treatment and Qulipta (atogepant) for prevention, which collectively ...

There are two types of CGRP medications: monoclonal antibodies and small-molecule antagonists (gepants). Both can be used to limit how often migraines occur, and how severe and how long the symptoms ...

Vyepti was approved by the FDA for the prevention of migraine in adults in 2020. As the last of the anti-CGRP mAbs to enter the migraine market, Vyepti has seen moderate uptake since its approval ...

SAN DIEGO -- Fremanezumab (Ajovy) cut monthly migraine days in children and adolescents with episodic migraine, according to the SPACE trial. The phase III study showed a reduction in monthly ...

Key opinion leaders (KOLs) previously interviewed by GlobalData had noted that the gepants had similar efficacy to the triptans and as such, favourable patient opinions of gepants could increase ...

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.

The following is a summary of “A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland,” ...